587 F.3d 1375, 2009 U.S. App. LEXIS 26568 (Fed. Cir. 2009) (MICHEL & Prost; NEWMAN, dissenting)
MAJOR ISSUES: Standing to sue–dismissal without prejudice
Agreement transferring patents
Exception for patents and applications “related to” pending litigation
F.3d—-, 2009 U.S. App. LEXIS 27330 (Fed. Cir. 2009) (RADER, Archer & Gajarsa)
MAJOR ISSUES: Summary judgment of noninfringement
Expert declaration by patent owner–conclusory statements not sufficient to survive summary judgment motion
Expert conclusory statements on infringement–failure to link to particular structures in accused device
Means-plus-function limitations
F.3d –, 2009 U.S. App. LEXIS 27648 (Fed. Cir. 2009) (DYK & Bryson; CLEVENGER, dissenting)
MAJOR ISSUES: Design patents; ordinary observer standard for anticipation and obviousness; minor variations not avoiding anticipation; design as a whole; features visible any time during product’s life
Bilski v. Kappos, 130 S. Ct. 3218, CPLRG 0015 (2010) (KENNEDY, Roberts, Thomas, Alito & Scalia (except for Parts II-B-2 and II-C-2), STEVENS, Ginsburg, Breyer & Sotomayor, concurring; BREYER & Scalia (as to Part II), concurring)
MAJOR ISSUES: Business method patents; “process” in Section 101; exceptions for abstract ideas, natural phenomena, and laws of nature Read CPLRG™ 0015
Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (En Banc) (LOURIE, Michel, Newman, Mayer, Bryson, Gajarsa, Dyk & Prost; NEWMAN, additional views; GAJARSA, concurring; RADER & Linn, dissenting-in-part & concurring-in-part; LINN & Rader, dissenting-in-part & concurring-in-part)
MAJOR ISSUES: Written description of invention (Section 112); requirement separate from enablement; original claims; support for generic claims; invention described by biological function Read CPLRG™ 0016
